INDICATIONS AND USAGE
Toviaz is a muscarinic antagonist indicated for the treatment of overactive
bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)
DOSAGE AND ADMINISTRATION-------------------------------------
The recommended starting dose of Toviaz is 4 mg once daily. Based upon
individual response and tolerability, the dose may be increased to 8 mg once
The daily dose of Toviaz should not exceed
4 mg in the following populations:
-Patients with severe renal impairment (CLCR <30 mL/min)
-Patients taking potent CYP3A4 inhibitors, such as ketoconazole,
itraconazole, and clarithromycin.
Toviaz is not recommended for use in patients with severe hepatic impairment
Toviaz should be taken with liquid and swallowed whole. Toviaz can be
administered with or without food, and should not be chewed, divided, or
DOSAGE FORMS AND STRENGTHS
Toviaz 4 mg extended-release tablets are light blue, oval, biconvex,
film-coated, and engraved with "FS" on one side.
Toviaz 8 mg extended-release tablets are blue, oval, biconvex, film-coated, and
engraved with "FT" on one side.
The daily dose of Toviaz should not exceed 4 mg in patients with
severe renal impairment (CLCR <30 mL/min).
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read